Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial

Xiaochu Man(Shandong Tumor Hospital), Changrui Liu(Chinese People's Liberation Army), Jie Huang(Shandong Tumor Hospital), Fangchao Zheng(Shandong Tumor Hospital), Shujuan Sun(Shandong Tumor Hospital), Xianguang Zhao(Fudan University), Baoxuan Zhang(Chongqing University), Qingqing He(Chinese People's Liberation Army), Xinzhao Wang(Shandong Tumor Hospital), Bingjie Fan(Shandong Tumor Hospital), Chao Li(Shandong University), Linlin Wang(Qingdao University), Lin Dong(State Key Laboratory of Pollution Control and Resource Reuse), Zhengbo Zhou(Shandong Tumor Hospital), Dongdong Zhou(Hainan University), Hui Fu(Tianjin University of Traditional Chinese Medicine), Jinming Yu(Shandong University), Wei Huang(Central South University), Yan Zhang(Qingdao University), Shu Fang(Peking University), Liang Xu(Target (United States)), Xiao Sun(Shandong Tumor Hospital), Lihua Song(Shandong Tumor Hospital)
Clinical and Translational Medicine
May 1, 2024
Cited by 6


Related Papers